Sei Investments Co. Acquires 11,321 Shares of Neurocrine Biosciences, Inc. (NBIX)
Sei Investments Co. grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 10.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 117,710 shares of the company’s stock after purchasing an additional 11,321 shares during the quarter. Sei Investments Co. owned approximately 0.13% of Neurocrine Biosciences worth $7,213,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. The Manufacturers Life Insurance Company raised its holdings in shares of Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after purchasing an additional 193 shares in the last quarter. World Asset Management Inc bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at about $246,000. ARS Investment Partners LLC bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at about $207,000. Stephens Inc. AR bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at about $207,000. Finally, Crossmark Global Holdings Inc. bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at about $286,000.
Several research firms have recently commented on NBIX. BMO Capital Markets boosted their price target on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a report on Friday, August 4th. Oppenheimer Holdings, Inc. boosted their price target on shares of Neurocrine Biosciences from $70.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. Piper Jaffray Companies set a $68.00 price target on shares of Neurocrine Biosciences and gave the company a “buy” rating in a report on Thursday, August 24th. Citigroup Inc. restated a “buy” rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $86.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $78.88.
In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 26,250 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the sale, the insider now owns 144,601 shares of the company’s stock, valued at approximately $8,676,060. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Darin Lippoldt sold 9,900 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total transaction of $723,195.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 150,710 shares of company stock worth $9,758,593. 4.80% of the stock is owned by insiders.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at $71.81 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. Neurocrine Biosciences, Inc. has a 52 week low of $37.35 and a 52 week high of $75.98.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to the consensus estimate of $29.38 million. During the same quarter last year, the firm earned ($0.43) EPS. research analysts expect that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current fiscal year.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.